Several drugs targeting Notch signaling including γ-secretase inhibitors (such as RO4929097) [64] and anti-DLL-4 antibodies (such as demcizumab [65] and enoticumab [66]) are currently under clinical trials for different cancers as monotherapy or in combination with other treatments. Here, DLL4 is linked to cancer.